These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36463731)

  • 41. A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
    Pauli C; Bochtler T; Mileshkin L; Baciarello G; Losa F; Ross JS; Pentheroudakis G; Zarkavelis G; Yalcin S; Özgüroğlu M; Beringer A; Scarato J; Mueller-Ohldach M; Thomas M; Moch H; Krämer A
    Oncologist; 2021 May; 26(5):e769-e779. PubMed ID: 33687747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
    Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
    Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
    Varadhachary G
    Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Radiological diagnostics in CUP syndrome].
    Kazmierczak PM; Nikolaou K; Rominger A; Graser A; Reiser MF; Cyran CC
    Radiologe; 2014 Feb; 54(2):117-23. PubMed ID: 24500247
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accurate classification of metastatic brain tumors using a novel microRNA-based test.
    Mueller WC; Spector Y; Edmonston TB; St Cyr B; Jaeger D; Lass U; Aharonov R; Rosenwald S; Chajut A
    Oncologist; 2011; 16(2):165-74. PubMed ID: 21273512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extensive diagnostic work-up for patients with carcinoma of unknown primary.
    Meijer L; Verhoeven RHA; de Hingh IHJT; van de Wouw AJ; van Laarhoven HWM; Lemmens VEPP; Loef C
    Clin Exp Metastasis; 2021 Apr; 38(2):231-238. PubMed ID: 33515369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?
    Rassy E; Parent P; Lefort F; Boussios S; Baciarello G; Pavlidis N
    Crit Rev Oncol Hematol; 2020 Mar; 147():102882. PubMed ID: 32106012
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
    Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
    Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP).
    Es HA; Mahdizadeh H; Asl AAH; Totonchi M
    Sci Rep; 2021 Jul; 11(1):15112. PubMed ID: 34302033
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical Practice of Carcinoma of Unknown Primary].
    Hasegawa Y; Mukai H
    Gan To Kagaku Ryoho; 2018 Jun; 45(6):891-893. PubMed ID: 30026408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP).
    Davalos V; Esteller M
    EMBO Mol Med; 2020 Jul; 12(7):e12685. PubMed ID: 32558182
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP).
    Haas I; Hoffmann TK; Engers R; Ganzer U
    Eur Arch Otorhinolaryngol; 2002 Jul; 259(6):325-33. PubMed ID: 12115082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
    Greco FA
    Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.
    Penson A; Camacho N; Zheng Y; Varghese AM; Al-Ahmadie H; Razavi P; Chandarlapaty S; Vallejo CE; Vakiani E; Gilewski T; Rosenberg JE; Shady M; Tsui DWY; Reales DN; Abeshouse A; Syed A; Zehir A; Schultz N; Ladanyi M; Solit DB; Klimstra DS; Hyman DM; Taylor BS; Berger MF
    JAMA Oncol; 2020 Jan; 6(1):84-91. PubMed ID: 31725847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay.
    Raghav K; Overman M; Poage GM; Soifer HS; Schnabel CA; Varadhachary GR
    Oncologist; 2020 Nov; 25(11):e1807-e1811. PubMed ID: 32893931
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
    Wardell CP; Fujita M; Yamada T; Simbolo M; Fassan M; Karlic R; Polak P; Kim J; Hatanaka Y; Maejima K; Lawlor RT; Nakanishi Y; Mitsuhashi T; Fujimoto A; Furuta M; Ruzzenente A; Conci S; Oosawa A; Sasaki-Oku A; Nakano K; Tanaka H; Yamamoto Y; Michiaki K; Kawakami Y; Aikata H; Ueno M; Hayami S; Gotoh K; Ariizumi SI; Yamamoto M; Yamaue H; Chayama K; Miyano S; Getz G; Scarpa A; Hirano S; Nakamura T; Nakagawa H
    J Hepatol; 2018 May; 68(5):959-969. PubMed ID: 29360550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.